NYSEArca - Delayed Quote USD

SPDR S&P Retail ETF (XRT)

73.22 +1.01 (+1.40%)
At close: April 26 at 4:00 PM EDT
73.22 -0.07 (-0.09%)
After hours: April 26 at 4:06 PM EDT
Key Events
Loading Chart for XRT
DELL
  • Previous Close 72.21
  • Open 72.26
  • Bid 72.99 x 1400
  • Ask 73.34 x 3200
  • Day's Range 72.23 - 73.49
  • 52 Week Range 56.20 - 79.12
  • Volume 6,749,626
  • Avg. Volume 6,540,604
  • Net Assets 509.47M
  • NAV 73.29
  • PE Ratio (TTM) 12.99
  • Yield 1.21%
  • YTD Daily Total Return 1.45%
  • Beta (5Y Monthly) 1.32
  • Expense Ratio (net) 0.35%

In seeking to track the performance of the S&P Retail Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the retail segment of the S&P Total Market Index ("S&P TMI").

SPDR State Street Global Advisors

Fund Family

Consumer Cyclical

Fund Category

509.47M

Net Assets

2006-06-19

Inception Date

Performance Overview: XRT

Trailing returns as of 4/26/2024. Category is Consumer Cyclical.

YTD Return

XRT
1.45%
Category
7.83%
 

1-Year Return

XRT
22.37%
Category
25.66%
 

3-Year Return

XRT
5.89%
Category
1.14%
 

People Also Watch

Holdings: XRT

Top 10 Holdings (16.03% of Total Assets)

SymbolCompany% Assets
GPS
The Gap, Inc. 1.78%
DKS
DICK'S Sporting Goods, Inc. 1.68%
GES
Guess?, Inc. 1.65%
JWN
Nordstrom, Inc. 1.60%
FL
Foot Locker, Inc. 1.59%
AAP
Advance Auto Parts, Inc. 1.57%
DDS
Dillard's, Inc. 1.57%
AEO
American Eagle Outfitters, Inc. 1.56%
ABG
Asbury Automotive Group, Inc. 1.52%
BBWI
Bath & Body Works, Inc. 1.51%

Sector Weightings

SectorXRT
Healthcare   2.82%
Energy   1.38%
Technology   1.16%
Real Estate   0.00%
Utilities   0.00%
Industrials   0.00%

Recent News: XRT

Research Reports: XRT

  • Analyst Report: Biogen Inc.

    Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

    Rating
    Price Target
     
  • MOS: What does Argus have to say about MOS?

    MOSAIC CO/THE has an Investment Rating of HOLD; a target price of $32.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Price Target
     
  • MOS: Raising target price to $34.00

    MOSAIC CO/THE has an Investment Rating of HOLD; a target price of $34.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Price Target
     
  • MOS: Lowering target price to $32.00

    MOSAIC CO/THE has an Investment Rating of HOLD; a target price of $32.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Price Target
     

Related Tickers